ENTBF - Entheon Biomedical completes acquisition of Lobo Genetics

Entheon Biomedical (OTCQB:ENTBF) completed the acquisition of Lobo Genetics in a stock deal. Lobo is a genetics company with a direct-to-consumer platform, used in the psychedelics and cannabis spaces to provide personalized insights into an individual's response to hallucinogenic and psychoactive drugs. Entheon issued 5M common shares to former Lobo shareholders and also issued a total of 9,603 incentive stock options to Lobo stock option holders. Lobo's founder and former CEO John Lem will serve as a strategic advisor of industry affairs on Entheon's advisory board. Lem was also granted 200K stock options, each option is exercisable for one common stock at C$0.33 per share. "With increased capacity to screen patients, on a genetic basis, for underlying psychiatric disorders prior to undertaking PAP (psychedelic-assisted psychotherapeutic), Entheon is furthering its commitment toward safety and predictability in psychedelic therapies while aggregating data that can be used to determine which psychedelic molecules are best-suited

For further details see:

Entheon Biomedical completes acquisition of Lobo Genetics